Loading...
XSTO
ERMA
Market cap15mUSD
Jun 09, Last price  
2.17SEK
1D
1.22%
1Q
-9.45%
Jan 2017
-71.72%
IPO
-66.94%
Name

Enorama Pharma AB

Chart & Performance

D1W1MN
P/E
—
P/S
8.32
EPS
—
Div Yield, %
—
Shrs. gr., 5y
55.24%
Rev. gr., 5y
15.68%
Revenues
16m
+1,061.12%
1,383,2431,993,7783,991,2041,572,8905,256,0117,610,7172,146,00011,036,0006,847,0001,358,00015,768,000
Net income
-44m
L-1.81%
-20,000-656,000-7,836,114-8,755,754-16,339,339-24,721,571-23,901,000-28,544,000-41,780,000-44,613,000-43,806,000
CFO
-36m
L-13.66%
307,000480,000-6,114,487-6,666,545-13,360,169-26,563,507-22,998,000-30,164,000-32,958,000-41,349,000-35,702,000

Profile

Enorama Pharma AB (publ), a pharmaceutical company, develops, manufactures, and sells medicated chewing gum containing proven generic substances in Sweden. It offers nicotine chewing gum for smoking cessation and medical cannabis chewing gums for non-pharma applications, as well as for other applications, such as oromucosal drug delivery and allergic rhinitis. The company is based in Malmö, Sweden.
URL
https://www.enorama.se/
IPO date
Jun 10, 2016
Employees
9
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
15,768
1,061.12%
1,358
-80.17%
6,847
-37.96%
Cost of revenue
12,065
8,130
10,335
Unusual Expense (Income)
NOPBT
3,703
(6,772)
(3,488)
NOPBT Margin
23.48%
Operating Taxes
(250)
Tax Rate
NOPAT
3,703
(6,772)
(3,238)
Net income
(43,806)
-1.81%
(44,613)
6.78%
(41,780)
46.37%
Dividends
Dividend yield
Proceeds from repurchase of equity
40,402
43,126
9,000
BB yield
-19.88%
-50.23%
-25.99%
Debt
Debt current
133
1,464
Long-term debt
303
445
Deferred revenue
Other long-term liabilities
4,326
4,326
Net debt
(2,085)
(5,717)
(2,230)
Cash flow
Cash from operating activities
(35,702)
(41,349)
(32,958)
CAPEX
Cash from investing activities
Cash from financing activities
35,287
41,863
25,345
FCF
(561)
(6,095)
(1,936)
Balance
Cash
2,085
6,153
4,139
Long term investments
Excess cash
1,297
6,085
3,797
Stockholders' equity
9,449
(185,783)
(142,448)
Invested Capital
6,506
210,083
179,779
ROIC
3.42%
ROCE
47.46%
EV
Common stock shares outstanding
60,473
27,696
9,488
Price
3.36
8.39%
3.10
-15.07%
3.65
-83.60%
Market cap
203,190
136.66%
85,859
147.92%
34,632
-79.29%
EV
201,105
80,142
32,402
EBITDA
24,113
(3,224)
49
EV/EBITDA
8.34
661.27
Interest
2,990
883
1,273
Interest/NOPBT
80.75%